FDA-Approved IHC Tests to Assess Tumor PD-L1 Expression in NSCLC Now Available at PhenoPath, PD-L1 (Clones 22C3 and 28-8)

Share Article

PhenoPath is pleased to announce the availability of two new FDA-approved IHC tests for PD- L1 (clones 22C3 and 28-8): 1) PD-L1 IHC 22C3 pharmDx test, the FDA-approved companion diagnostic to assess tumor PD-L1 expression in non-small cell lung carcinoma (NSCLC) patients, to determine eligibility for KEYTRUDA® (pembrolizumab) anti-PD1 therapy; and 2) PD-L1 IHC 28-8 pharmDx test, the FDA-approved complementary diagnostic to assess tumor PD-L1 expression in NSCLC patients, to determine eligibility for OPDIVO® (nivolumab) anti- PD1 therapy.

PD-L1

We are excited that PhenoPath can serve as a resource to the pathology and oncology communities in offering the various companion and complementary PD-L1 IHC assays to permit optimal patient treatment.

“This new class of drugs, targeting the PD-L1/PD1 immune checkpoint, promises to revolutionize treatment of a number of malignancies, including non small cell lung carcinoma, melanoma, renal cell carcinoma, and others. We are excited that PhenoPath can serve as a resource to the pathology and oncology communities in offering the various companion and complementary PD-L1 IHC assays to permit optimal patient treatment.”

Allen M. Gown, MD
Founder & Medical Director
PhenoPath

Physicians can order both the Dako PD-L1 IHC 22C3 pharmDx and Dako PD-L1 IHC 28-8 pharmDx immunohistochemistry tests directly from PhenoPath, in addition to a generic PD-L1 expression immunohistochemistry test employing Cell Signaling Technology’s EIL3N antibody clone. PhenoPath is one of the first laboratories in the nation to have all these assays validated and available.

Read more:
http://phenopath.com/#/news/pd-l1-ihc-22c3-pharmdx
http://phenopath.com/#/news/pd-l1-ihc-28-8-pharmdx

About PhenoPath:
PhenoPath is a national and internationally-recognized physician-owned and directed specialty pathology consultative practice and reference laboratory providing diagnostic and BioPharma pathology services in the U.S., Canada and around the world. In addition to a broad range of consultative expertise in solid tumor and hematolymphoid tumors, PhenoPath is on the forefront of state-of-the-art technologies, including immunohistochemistry, flow cytometry, fluorescence in situ hybridization and molecular assays as well as chromosome analysis. For more information, contact us at 888-927-4366.

Contacts: Dr. Allen M. Gown, Dr. Regan Fulton

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sheri Storey
PhenoPath
+1 (206) 374-9000
Email >
Visit website